Repeated intranigral MPTP administration: A new protocol of prolonged locomotor impairment mimicking Parkinson's disease

Journal of Neuroscience Methods

Volumn 167, Issue 2, 2008, Pages 268-277

  Reksidler, Angela Braga ^a   Lima, Marcelo Meira Santos ^b   Dombrowski, Patrícia ^a   Andersen, Monica Levy ^b   Zanata, Sílvio Marques ^a   Andreatini, Roberto ^a   Tufik, Sergio ^b   Vital, Maria Aparecida Barbato Frazão ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Animal model; Intranigral; MPTP; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; IMMUNOREACTIVITY; LOCOMOTION; MALE; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; TIME; WISTAR RAT; ZONA COMPACTA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION; MALE; MOTOR ACTIVITY; NEUROTOXINS; PARKINSON DISEASE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 36849001892     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2007.08.024     Document Type: Article

References (36)

1. Ballard P.A., Tetrud J., and Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35 (1985) 949-956
2. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2 (2001) 325-334
3. Bjijou Y., De Deurwaerdere P., Spampinato U., Stinus L., and Cador M. d-Amphetamine-induced behavioral sensitization: effect of lesioning dopaminergic terminals in the medial prefrontal cortex, the amygdala and the entorhinal cortex. Neuroscience 109 (2002) 499-516
4. Blandini F., Nappi G., Tassorelli C., and Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Neurobiology 62 (2000) 63-88
5. Braga R., Kouzmine I., Canteras N.S., and Da Cunha C. Lesion of the substantia nigra pars compacta impairs delayed alternation in a Y-maze in rats. Exp. Neurol. 192 (2005) 134-141
6. Cador M., Bjijou Y., and Stinus L. Evidence of a complete independence of the neurobiological substrates for the induction and expression of behavioral sensitization to AMPH. Neuroscience 65 (1995) 385-395
7. Chiba K., Trevor A., and Castagnoli Jr. N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120 (1984) 574-578
8. Da Cunha C., Gevaerd M.S., Vital M.A.B.F., Miyoshi E., Andreatini R., Silveira R., Takahashi R., and Canteras N.S. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav. Brain Res. 124 (2001) 9-18
9. Da Cunha C., Angellucci M.E.M., Canteras N.S., Wonnacott S., and Takahashi R.N. The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cell. Mol. Neurobiol. 22 (2002) 227-237
10. Del Arco A., Segovia G., Canales J.J., Garrido P., Blas M., García-Verdugo J.M., and Mora F. Environmental enrichment reduces the function of D1 dopamine receptors in the prefrontal cortex of the rat. J. Neural. Transm. 114 (2007) 43-48
11. Drolet R.E., Behrouz B., Lookingland K.J., and Goudreau J.L. Mice lacking α-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 25 (2004) 761-769
12. Eberhardt O., and Schulz J.B. Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicol. Lett. 139 (2003) 135-151
13. Eidelberg E., Brooks B.A., Morgan W.W., Walden J.G., and Kokemoor R.H. Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys. Neuroscience 18 (1986) 817-822
14. Ferraz A.C., Xavier L.L., Hernandez S., Sulzbach M., Viola G.G., Anselmo-Franci J.A., Achaval M., and Da Cunha C. Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6 hydroxydopamine. Brain Res. 986 (2003) 200-205
15. Ferro M.M., Bellíssimo M.I., Anselmo-Franci J.A., Angellucci M.E.M., Canteras N.S., and Da Cunha C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J. Neurosci. Methods 148 (2005) 78-87
16. Fornai F., Schlüter O.M., Lenzi P., Gesi M., Ruffoli R.F., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paperelli A., and Sudhof T.C. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and α-synuclein. Proc. Natl. Acad. Sci. 102 (2005) 3413-3418
17. Franco J., Prediger R.D., Pandolfo P., Takahashi R.N., Farina M., and Dafre A.L. Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb. Life Sci. 80 (2007) 1906-1914
18. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
19. Lima M.M.S., Reksidler A.B., Zanata S.M., Machado H.B., Tufik S., and Vital M.A.B.F. Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res. 1101 (2006) 117-125
20. Lima M.M.S., Andersen M.L., Reksidler A.B., Vital M.A.B.F., and Tufik S. The role of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS ONE 2 6 (2007) e513
21. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin protein reagent. J. Biol. Chem. 193 (1951) 265-275
22. Meredith G.E., Totterdell S., Petroske E., Santa Cruz K., Callison Jr. R.C., and Lau Y. Lysosomal malfunction accompanied alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 956 (2002) 156-165
23. Miyoshi E., Wietzikoski S., Camplessei M., Silveira R., Takahashi R.N., and Da Cunha C. Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced nigral lesion. Brain Res. Bull. 58 (2002) 41-47
24. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 5th ed. (2005), Academic Press, San Diego
25. Perry J.C., Vital M.A.B.F., Frussa-Filho R., Tufik S., and Palermo-Neto J. Monosialoganglioside (GM1) attenuates the behavioural effects of longterm haloperidol administration in supersensitive rats. Eur. Neuropsychopharmacol. 14 (2004) 127-133
26. Perry J.C., Hipólide D.C., Tufik S., Martins R.D., Da Cunha C., Andreatini R., and Vital M.A.B.F. Intra-nigral MPTP lesion in rats: behavioral and autoradiography studies. Exp. Neurol. 195 (2005) 322-329
27. Petroske E., Meredith G.E., Callen S., Totterdell S., and Lau Y.S. Mouse model of parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106 (2001) 589-601
28. Prediger R.D.S., Batista L.C., Medeiros R., Pandolfo P., Florio J.C., and Takahashi R.N. The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp. Neurol. 202 (2006) 391-403
29. Queiroz C.M.T., Alcântara F.B., Yagüe A.M.L., Bibancos T., and Frussa-Filho R. Acute buspirone abolishes the expression of behavioral dopaminergic supersensitivity in mice. Braz. J. Med. Biol. Res. 35 (2002) 237-242
30. Reksidler A.B., Lima M.M.S., Zanata S.M., Machado H.B., Da Cunha C., Andreatini R., Tufik S., and Vital M.A.B.F. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur. J. Pharmacol. 560 (2007) 163-175
31. Smeyne R.J., and Jackson-Lewis V. The MPTP model of Parkinson's disease. Mol. Brain Res. 134 (2005) 57-66
32. Sotnikova T.D., Beaulieu J.-M., Barak L.S., Wetsel W.C., Caron M.G., and Gainetdinov R.R. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson's disease. PLoS Biol. 3 (2005) e271
33. Vezina P. Amphetamine injected into the ventral tegmental area sensitizes the nucleus accumbens dopaminergic response to systemic amphetamine: an in vivo microdialysis study in the rat. Brain Res. 605 (1993) 332-337
34. von Bohlen, and Halbach O. Animal models of Parkinson's disease. Neurodegener. Dis. 2 (2005) 313-320
35. +). Exp. Neurol. 200 (2006) 172-183
36. Zadicario P., Ronen S., and Eilam D. Modulation of quinpirole-induced compulsive-like behavior in rats by environmental changes: implications for OCD rituals and for exploration and navigation. BMC Neurosci. 8 (2007) 23